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ctin (thin) ﬁlament length regulation and stability are
essential for striated muscle function. To determine
the role of the actin ﬁlament pointed end capping
protein, tropomodulin1 (Tmod1), with tropomyosin, we
generated monoclonal antibodies (mAb17 and mAb8)
against Tmod1 that speciﬁcally disrupted its interaction with
tropomyosin in vitro. Microinjection of mAb17 or mAb8
into chick cardiac myocytes caused a dramatic loss of the
thin ﬁlaments, as revealed by immunoﬂuorescence decon-
volution microscopy. Real-time imaging of live myocytes
expressing green ﬂuorescent protein–
 
 
 
-tropomyosin and
A
 
microinjected with mAb17 revealed that the thin ﬁlaments
depolymerized from their pointed ends. In a thin ﬁlament
reconstitution assay, stabilization of the ﬁlaments before the
addition of mAb17 prevented the loss of thin ﬁlaments.
These studies indicate that the interaction of Tmod1 with
tropomyosin is critical for thin ﬁlament stability. These data,
together with previous studies, indicate that Tmod1 is a
multifunctional protein: its actin ﬁlament capping activity
prevents thin ﬁlament elongation, whereas its interaction
with tropomyosin prevents thin ﬁlament depolymerization.
 
Introduction
 
The regulation of actin dynamics in eukaryotic cells is essential
for diverse processes including migration, membrane pro-
trusion, cytokinesis, and contraction. Striated muscle has
proven to be a powerful model system for investigating
actin (thin) filament dynamics because within myofibrils,
actin monomers are precisely assembled and maintained in
filaments with strikingly uniform lengths. These properties
are critical for proper contractile function and appear to
involve several mechanisms, including interactions with
other sarcomeric proteins.
At the Z-lines, the borders of individual sarcomeres, the
barbed (plus or fast-growing) ends of the thin filaments are
capped by CapZ; thereby, the thin filaments are prevented
from elongating or shortening from their barbed ends.
Along the length of the thin filaments, tropomyosin, an
 
 
 
-helical rodlike molecule, forms hetero- and homodimers
in a head-to-tail fashion. One well-established role of tro-
pomyosin is to cooperate with the troponin complex
in regulating the Ca
 
2
 
 
 
-dependent actomyosin interaction
(Huxley, 1969; for review see Cooke, 1997). However,
mounting evidence from a number of in vitro studies indicate
that tropomyosin also functions to stabilize the thin filaments.
Tropomyosin increases filament stiffness, prevents fragmenta-
tion and bending, and prevents depolymerization of actin
monomers from their pointed (minus or slow-growing)
ends (Wegner, 1982; Broschat et al., 1989; Weigt et al.,
1990; Adami et al., 2002). Tropomyosin also enhances
actin filament assembly and physically protects thin filaments
from the depolymerizing effects of ADF/cofilin or gelsolin
(Ono and Ono, 2002; Nyakern-Meazza et al., 2002; for
review see Cooper, 2002). In vivo studies have revealed a
critical role for tropomyosin in proper muscle function. For
example, homozygous 
 
 
 
-tropomyosin null mice are embry-
onic lethal, whereas heterozygous knockout mice show no
obvious phenotype (Blanchard et al., 1997; Rethinasamy et
al., 1998). In 
 
Drosophila
 
, mutations of one muscle tropomyo-
sin isoform (
 
Tm1
 
) result in disruption of peripheral, but
not central, myofibrillar organization, as well as alterations
in force-generating properties (Kreuz et al., 1996). Studies
in 
 
Caenorhabditis elegans
 
 demonstrate that suppression of
tropomyosin expression leads to disorganized sarcomeric
actin filaments and muscle paralysis (Ono and Ono, 2002).
However, the precise mechanisms by which tropomyosin
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contributes to thin filament stability remain unclear, partic-
ularly in vertebrate muscle.
Another sarcomeric protein known to be critical for thin
filament length regulation is tropomodulin 1 (Tmod1/E-
Tmod), which caps the pointed ends of the thin filaments in
cardiac muscle cells as well as in other cell types (for review
see Weber, 1999). Unlike other actin capping proteins,
Tmod1 also binds tropomyosin. Tmod1 completely blocks
elongation and depolymerization from the pointed ends of
actin filaments in the presence of tropomyosin in vitro
(
 
K
 
d
 
 
 
 
 
 50 pM). However, in the absence of tropomyosin,
Tmod1 has a lower affinity for the pointed ends (
 
K
 
d
 
 
 
 
 
 0.1–
0.2 
 
 
 
M) and its capping activity is down-regulated 
 
 
 
1,000-
fold (Weber et al., 1994, 1999). Based on additional bio-
chemical analyses, it was proposed that Tmod1 may also
contribute to thin filament length regulation by prevent-
ing additional tropomyosin molecules from binding to the
pointed ends of the actin filaments, thus acting as a tro-
pomyosin capping molecule (Wegner, 1979; Fowler, 1990;
Fowler et al., 1993).
Tmod1’s dual interactions with tropomyosin and actin
filaments are reflected by its distinct structure. Its COOH-
terminal half is compact and tightly folded (Kostyukova
et al., 2000). It is this half of the molecule that possesses
the primary actin filament capping activity (Fowler et al.,
2003). In contrast, Tmod1’s NH
 
2
 
-terminal half is highly
flexible and elongated (Kostyukova et al., 2000), and con-
tains overlapping binding sites for both muscle and non-
muscle tropomyosins (Babcock and Fowler, 1994; Vera et
al., 2000). Tmod1 also interacts with the extreme NH
 
2
 
-ter-
minal modules of the giant striated muscle protein, nebulin.
Although the significance of this interaction is unknown, it
is intriguing to speculate that its role is consistent with neb-
ulin’s proposed function as a thin filament ruler that defines
their uniform lengths (McElhinny et al., 2001). The exist-
ence of several Tmod1-interacting molecules in striated
muscle suggests that Tmod1 may play multiple roles in thin
filament length regulation.
The physiological roles of Tmod1 in cardiac muscle cells
have been investigated in several studies. For example, de-
creasing levels of endogenous Tmod1 in rat cardiac myo-
cytes resulted in abnormally long thin filaments (Sussman
et al., 1998a). In contrast, overexpression of Tmod1 in rat
and chick cardiac myocytes, or Sanpodo (a Tmod homo-
logue) in 
 
Drosophila,
 
 resulted in shorter thin filaments
(Sussman et al., 1998a; Littlefield et al., 2001; Mardahl-
Dumesnil and Fowler, 2001). Transgenic mice overex-
pressing Tmod1 (TOT) in their myocardium exhibited
myofibril disarray and dilated cardiomyopathy (Sussman et
al., 1998b), and Tmod1
 
 
 
/
 
 
 
 mouse embryos die at approxi-
mately day E10, suggesting an essential role for Tmod1 in
myofibril assembly (Chu et al., 2003; unpublished data).
Therefore, the levels of Tmod1 expression are important in
maintaining the lengths of thin filaments and myofibril ar-
chitecture in vivo.
The functional role of Tmod1’s actin filament pointed
end capping activity has been investigated directly in studies
using primary cultures of chick cardiac myocytes. Microin-
jection of a monoclonal antibody that specifically blocked
Tmod1’s actin capping activity (but not its interaction with
tropomyosin), resulted in an abnormal elongation of the ac-
tin filaments from their pointed ends and abolished contrac-
tile activity (Gregorio et al., 1995). Thus, Tmod1’s actin fil-
ament capping activity is required to maintain the lengths of
the mature thin filaments in cardiac muscle. Interestingly, in
these studies, Tmod1 and tropomyosin remained associated
with the thin filaments. Therefore, it has remained unclear
what exactly is the function of Tmod1–tropomyosin interac-
tions in thin filament length regulation.
Here, we sought to investigate the functional properties of
the interaction of Tmod1 with tropomyosin on thin fila-
ment length and stability in cardiac muscle. We determined
that blocking the interaction of Tmod1 with tropomyosin in
live cardiac myocytes resulted in a dramatic loss of thin fila-
ments and subsequent contractile activity. The disappear-
ance of thin filaments was visualized in real time and oc-
curred from their pointed ends toward the Z-line. Our data
indicate that the actin- and tropomyosin-binding activities
of Tmod1 have unique and complementary functional roles.
The actin capping activity of Tmod1 inhibits actin elonga-
tion and maintains the lengths of the thin filaments (Grego-
rio et al., 1995), whereas the tropomyosin-binding domain
of Tmod1 appears to stabilize the thin filaments by prevent-
ing depolymerization from their pointed ends. These studies
indicate that the regulated activity of Tmod1 is essential for
proper muscle function.
 
Results
 
Two anti-Tmod1 monoclonal antibodies specifically 
recognize the NH
 
2
 
-terminal region of Tmod1 
and perturb its interaction with tropomyosin
 
To study the functional significance of the interaction of
Tmod1 with tropomyosin, we first sought to identify
monoclonal anti-Tmod1 antibodies that disrupted the in-
teraction of the molecules in vitro. Previous work showed
that the extreme NH
 
2
 
-terminal end of Tmod1 (amino ac-
ids 6–34) is essential for binding to skeletal muscle tro-
pomyosin (Babcock and Fowler, 1994). We generated two
monoclonal antibodies to chicken Tmod1 (mAb8 and
mAb17) that specifically recognized the NH
 
2
 
-terminal
end of Tmod1 by Western blot analysis (Fig. 1 b). Both
antibodies recognized full-length Tmod1 (Fig. 1 b, lane
1), and recombinant Tmod1 fragments including residues
6–184, 6–94 and 6–57, but failed to recognize fragments
including residues 35–359 and 95–359 (data shown for
mAb17). These results demonstrated that mAb17 and
mAb8 recognize epitopes within the NH
 
2
 
-terminal resi-
dues 6–34 of Tmod1, which contain the skeletal muscle
tropomyosin binding site. To demonstrate the specificity
of these antibodies, Western blot analyses of embryonic
chick cardiac myocyte extracts were performed, revealing
that mAb17 and mAb8 specifically recognized a single 40-
kD polypeptide, corresponding to the molecular mass of
Tmod1 (Fig. 1 c).
To determine whether mAb17 and mAb8 inhibited tro-
pomyosin binding to Tmod1, full-length recombinant
chick Tmod1 (25 nM) was absorbed onto nitrocellulose
dots. The dots were incubated with increasing concentra-T
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tions (0–700 nM) of mAb8 or mAb17 before the addi-
tion of 
 
125
 
I-labeled skeletal muscle tropomyosin. This ex-
periment demonstrated that a 10-fold molar excess over
Tmod1 of either mAb17 (open circles) or mAb8 (closed
squares) completely abolished 
 
125
 
I-tropomyosin binding
to Tmod1 (Fig. 1 d). In contrast, a 28-fold molar excess
of mAb9 (closed triangle), an antibody that recognizes
Tmod1’s COOH-terminal end and blocks its actin fila-
ment capping activity (Gregorio et al., 1995), had no effect
on 
 
125
 
I-tropomyosin binding to Tmod1 (Fig. 1 d). To test
whether mAb17 and mAb8 would also promote the disso-
ciation of 
 
125
 
I-tropomyosin from Tmod1, nitrocellulose
dots of Tmod1 were preincubated with 
 
125
 
I-tropomyosin
followed by incubation with a 13-fold molar excess of
those antibodies with respect to Tmod1. Both mAb17 and
mAb8 promoted dissociation of tropomyosin from Tmod1
within 60 min (Fig. 1 e, data shown for mAb8, closed
squares). In contrast, addition of equivalent molar ratios of
MOPC-21 did not result in a significant dissociation of
tropomyosin from Tmod1 (open circles). Fab fragments
of mAb8 also inhibited the interaction of Tmod1 with tro-
pomyosin indicating that this effect was not caused by
cross-linking Tmod1 by the bivalent antibody (unpub-
lished data). These results demonstrated that both mAb17
and mAb8 specifically disrupted the interaction of Tmod1
with tropomyosin in vitro.
 
Disrupting the interaction of Tmod1 with tropomyosin 
in live cardiac myocytes results in a reversible 
disassembly of thin filaments and cessation of beating
 
We next used mAb17 and mAb8 in microinjection studies
designed to investigate the interaction of Tmod1 with tro-
pomyosin in the context of living cardiac myocytes. Day 3–5
cardiac myocytes were microinjected with mAb17 or
mAb8 and incubated for 1 h after injection. The myocytes
were fixed and stained for thin filament components. A
few cells microinjected with mAb17 or mAb8 demon-
strated a thin filament pointed end striated staining pattern
for Tmod1 and unperturbed actin filaments (unpublished
data). However, the majority (
 
 
 
80%) of myocytes injected
with mAb17 (Fig. 2 c) or mAb8 (Fig. 2 e) exhibited a dra-
matic loss of actin filaments, as determined by staining with
fluorescently conjugated phalloidin (Fig. 2, d and f), com-
pared with the normal striated appearance of sarcomeric ac-
tin staining in cells injected with the control antibody
MOPC-21 (Fig. 2 b) or in surrounding uninjected cells
(Fig. 2 d, bottom). Additionally, staining with anti–cardiac
actin antibodies demonstrated that the absence of actin
staining was not due to an artifact from inhibition of phal-
loidin staining (Fig. 2 j). Notably, no Tmod1 striations were
detected (i.e., Tmod appeared diffused in the cytoplasm) in
the cells microinjected with mAb17 or mAb8, suggesting
that disrupting the interaction of Tmod1 with tropomyosin
promoted Tmod1’s dissociation from thin filament pointed
ends (Fig. 2, c and e). In the majority of cells (70–75%) per-
turbed by the microinjection of mAb17 or mAb8, no actin
filaments were detected (not depicted), whereas in other
cells remnants remained (Fig. 2, d, f, and j). Cells injected
with Fab fragments of mAb17 exhibited an identical pheno-
type, indicating that the loss of sarcomeric actin filament
staining was not due to Tmod1 cross-linking or sequestra-
tion in the cells (Fig. 2, i and j). The effect of mAb8 and
mAb17 was also not due to nonspecific effects of introduc-
ing any anti-Tmod1 monoclonal antibody into cardiac myo-
Figure 1. mAb17 and mAb8 specifically 
bind to the NH2-terminal Tmod1 residues 
6–57, recognize Tmod1 in embryonic 
chick heart lysates, and disrupt its inter-
action with tropomyosin. (a) Coomassie 
blue–stained gel of full-length Tmod1 
(lane 1,1–359) and Tmod1 fragments 
(lanes 2–6, residues 6–184, 35–359, 
95–359, 6–94, and 6–5, respectively). 
(b) Western blots of samples in panel a 
were probed with mAb17 that recognized 
full-length (lane 1) and NH2-terminal 
Tmod1 (lanes 2, 5, and 6), but not 
COOH-terminal Tmod1 (lanes 3 and 4). 
(c) Western blots of embryonic heart 
extracts were probed with secondary 
antibodies alone (2 
 alone), MOPC-21, 
mAb17, or mAb8. mAb8 and mAb17 
detected a band at  40 kD, correspond-
ing to Tmod1. (d) Tmod1 nitrocellulose 
dots were preincubated with mAb8, 
mAb17, or mAb9, followed by incubation 
with 
125I-tropomyosin (
125I-TM). Preincu-
bating the Tmod1 dots with increasing 
concentrations of mAb17 (closed squares) 
or mAb8 (open circles) resulted in a 
dramatic decrease in the percentage of 
tropomyosin that bound to Tmod1, as compared with mAb9 which did not disrupt the interaction (closed triangle). (e) Tmod1 dots were 
incubated with 
125I-tropomyosin (
125I-TM), followed by incubation with mAb8 (closed squares), or MOPC21 (open circles) for varying periods 
of time. Addition of mAb8 resulted in a significant dissociation of tropomyosin from Tmod1.T
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cytes. Microinjection of mAb95, another anti-Tmod1 anti-
body that recognizes an epitope close to the middle of the
molecule (unpublished data), or microinjection of mAb9,
that recognizes the COOH-terminal region of Tmod1 and
disrupts its capping activity, did not result in the loss of ac-
tin filament striations (Fig. 2, g and h; Gregorio et al.,
1995). In additional control experiments to examine for any
nonspecific effects on actin filaments, we found that micro-
injection of mAb17 into fibroblasts that contain actin stress
fibers but no detectable Tmod1 (Gregorio and Fowler,
1995) resulted in no observable effects on actin staining
(Fig. 2, k and l).
To determine whether injection of the function-blocking
antibodies had toxic effects on the myocytes, we tested
whether the phenotype was reversible by culturing the mi-
croinjected cells for longer time intervals to allow for poten-
tial degradation of the mAb17 Fabs and/or sequestration of
antibodies by newly synthesized Tmod1 before fixation. In
this experiment, cardiac myocytes plated on coverslips with
numbered grids (to identify injected cells) were injected with
mAb17 Fabs, incubated 24–48 h, fixed, and viewed. Nota-
bly, at these later time points, a partial reappearance of actin
filament striations was clearly seen at 24 h. By 48 h, a full re-
covery was observed in all cells that had been injected with
mAb17 Fabs, but had no detectable staining for the mAbs
(Fig. 2 m). These data indicate that the loss of sarcomeric ac-
tin filaments was reversible.
Next, to determine whether mAb17-induced Tmod1 and
actin disassembly was accompanied by disassembly of
tropomyosin, cells microinjected with mAb17 Fabs were
stained for tropomyosin. A loss of tropomyosin staining was
clearly observed, which is consistent with the loss of actin fil-
aments (see Fig. 4 b), indicating that the entire thin filament
had disassembled. This result suggested that the interaction
of Tmod1 with tropomyosin is necessary to stabilize the as-
sociation of tropomyosin with the actin filaments in cardiac
myocyte sarcomeres.
As a complementary approach to using anti-Tmod1 an-
tibodies to disrupt Tmod1’s interaction with tropo-
myosin, we microinjected a recombinant NH
 
2
 
-terminal
fragment of Tmod1 (1–130) into cardiac myocytes, con-
taining the tropomyosin binding site (Babcock and
Fowler, 1994; Greenfield and Fowler, 2002). Again, a loss
of actin filaments was observed (Fig. 2 o), likely due to
a dominant-negative mechanism; that is, the injected
Tmod1 fragment containing amino acids 1–130, likely
prevented endogenous Tmod1 from binding to endoge-
nous tropomyosin. These experiments support the hy-
pothesis that the interaction of Tmod1 with tropomyosin
is critical for actin filament stability.
The dramatic disappearance of thin filaments in microin-
jected cells suggested that contractile activity of the cells
would be inhibited. Indeed, beating activity was dramati-
cally diminished in cells microinjected with mAb17. Only
 
 
 
5% of those myocytes injected with mAb17 were observed
to beat 1 h after injection, compared with 
 
 
 
88% of those
cells injected with MOPC-21 (Table I). 100% of the unin-
jected cells that were beating at the onset of the experiment
Figure 2. Disruption of the interaction 
between Tmod1 and tropomyosin in 
live cardiac myocytes results in a loss of 
actin (thin) filaments. Cardiac myocytes 
were microinjected with MOPC-21 
(a and b), mAb17 (c and d), mAb17 Fab 
fragments (i and j), mAb8 (e and f), or 
mAb95 (g and h). Injected cells were 
observed using an AlexaFluor 594–
conjugated anti–mouse IgG to detect the 
injected antibody (a, c, and e). Micro-
injection of mAb17 or mAb8 resulted in 
a loss of actin filaments as detected by 
AlexaFluor 488 phalloidin (d and f, 
arrowheads) or using anti– -actin anti-
bodies (j, arrowheads). Normal actin 
filaments were seen in myocytes injected 
with MOPC-21 (b, arrows) or with 
mAb95 (h). Fibroblasts were also micro-
injected with mAb17 (k and l); no 
perturbation of actin filaments was seen 
(l). To test for recovery, injected cells 
were incubated for 48 h before staining. 
Actin filaments were easily visualized at 
this time point (m, arrows). A recombinant 
Tmod1 fragment containing residues 
1–130, mixed with MOPC-21 (n, to 
identify injected cells) was microinjected 
into cardiac myocytes and incubated for 
1 h. Microinjection of the Tmod1 
fragment containing the tropomyosin 
binding site resulted in a loss of actin 
filaments (o). Bars, 10  m.T
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remained beating after 1 h (unpublished data). In summary,
these data suggest that the Tmod1–tropomyosin interaction
is critical for thin filament stability and for contractile activ-
ity in cardiac myocytes.
 
Thin filaments depolymerize from their pointed ends 
in live cardiac myocytes
 
The data presented thus far indicated that thin filament
stability was compromised in cells in which the interaction
of Tmod1 with tropomyosin was disrupted. To address the
mechanism of how this disassembly occurred, we collected
time-lapse images of cells expressing GFP–
 
 
 
-tropomyosin
that were microinjected with mAb17. GFP–
 
 
 
-tropomyo-
sin assembled along the entire length of the thin filaments
in all myocytes where it was expressed (Helfman et al.,
1999). After injection with mAb17, striated GFP–
 
 
 
-tro-
pomyosin was observed to dissociate directly from the
pointed ends of the thin filaments in live cells (i.e.,
the  GFP–
 
 
 
-tropomyosin detectable at the Z-lines re-
mained at similar intensities, whereas the intensity from the
pointed ends greatly diminished). This dissociation from
the pointed ends was first noticeable at 30 min, with pro-
gressive dissociation only from the pointed ends up to 60 min
(Fig. 3); i.e., no detectable GFP–
 
 
 
-tropomyosin intensity
was lost from the sides of the filaments or from the Z-lines.
In contrast, injection of MOPC-21 had no effect on the
fluorescence intensity of GFP–
 
 
 
-tropomyosin. Interest-
ingly, the depolymerization effect on the thin filaments ap-
peared to occur with slower kinetics than that observed in
myocytes injected with mAb17, fixed, and then stained.
We speculate that this slower depolymerization effect was
due to overexpression of 
 
 
 
-tropomyosin in myocytes that
typically do not have a considerable pool of soluble tro-
pomyosin (Gregorio and Fowler, 1995) and/or alterations
in the stoichiometry of tropomyosin isoform expression
that may have further stabilized the thin filaments. The re-
sults from this experiment directly show that the loss of
thin filaments is due to the depolymerization of the fila-
ments from their pointed ends in cells. Furthermore, this
observation also suggests that Tmod1 acts as a “cap” to sta-
bilize tropomyosin’s association with the actin filament
pointed ends (Fowler et al., 1993), functioning with tro-
pomyosin to prevent actin filament depolymerization.
 
Thin filament disassembly is accompanied 
by perturbation of Z-lines, thick filaments, 
and titin filaments
 
To determine the effect that mAb17-induced thin filament
disassembly had on overall sarcomere organization, cells mi-
croinjected with MOPC-21 Fabs or mAb17 Fabs were
costained using AlexaFluor 488 phalloidin, together with
antibodies against 
 
 
 
-actinin, the major Z-line component;
myosin, the major thick filament component; as well as
I-band and M-line epitopes of titin. In cells injected with
mAb17 Fabs, 
 
 
 
-actinin (Fig. 4 d, red), myosin (Fig. 4 f,
red), and titin N2A and A168–170 epitopes (Fig. 4, h and j,
red), appeared disrupted along with the loss of actin fila-
ments (Fig. 4, d, f, h, and j, green). However, in some re-
gions, closely spaced remnants of a periodic striated staining
pattern for 
 
 
 
-actinin, titin, and myosin were observed
clearly in the absence of actin (Fig. 4, arrowheads). To con-
firm this observation, cells injected with mAb17 Fabs (Fig. 4
l) were triple labeled for actin (green), 
 
 
 
-actinin (red), and
M-line titin (blue). In some cells injected with mAb17 Fabs,
an alternating staining pattern of 
 
 
 
-actinin and M-line titin
(corresponding to alternating Z- and M-lines), was observed
in the absence of actin filaments in the identical myofibrils.
These data support previous studies that revealed that the
organization of thick filaments, as well as other sarcomeric
components, remained relatively intact in the absence of
thin filaments (von Arx et al., 1995; Linke et al., 1999).
Therefore, the perturbation of other sarcomeric filament sys-
 
Table I. 
 
mAb17 inhibits the contractile activity of chick 
cardiac myocyte
mAb No. of injected
myocytes
Percentage of 
cells beating
 
MOPC-21 251 87.8 
 
 
 
 3.0
17 255 5.6 
 
 
 
 5.1
 
a
a
 
P
 
  
 
 0.001 by 
 
t
 
 test.
Figure 3. Depolymerization of thin 
filaments from their pointed ends was 
visualized in live cells expressing GFP–
 -tropomyosin and microinjected with 
mAb17. Cardiac myocytes expressing 
GFP– -tropomyosin were microinjected 
with MOPC-21 (a–c) or mAb17 (d–f). 
Images were recorded every 15 min for 
1 h (data shown for preinjection, 30 and 
60 min). After 30 and 60 min, cells 
injected with mAb17 displayed thin 
filament shortening from their pointed 
ends (a–f, arrows). No depolymerization 
was observed in cells microinjected with 
MOPC-21. Bar, 5  m.T
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tems, as well as Z-lines, was likely secondary to the loss of
the thin filaments observed.
 
Stabilization of actin filaments in a thin filament 
reconstitution assay, before the disruption of the 
interaction of Tmod1 with tropomyosin, prevents 
thin filament depolymerization
 
To gain additional insights into the mechanism of the thin
filament disruption phenotype, we used a thin filament re-
constitution assay. This assay allows us to selectively study
the assembly properties of individual thin filament compo-
nents (in the absence of thick filament components), as
well as interfere with specific thin filament protein interac-
tions. Using this assay, we previously demonstrated that
binding of Tmod1 to the pointed ends of actin filaments
required the prior reconstitution of tropomyosin along
the actin filaments in “ghost myofibrils” (Gregorio and
Fowler, 1995). In brief, ghost myofibrils were prepared by
permeabilizing cardiac myocytes with saponin and extract-
ing them in 0.5 M KCl. Under these conditions, many sar-
comeric components including the thick filaments (Fig. 5
a) and the thin filament components, tropomyosin (Fig. 5
b) and Tmod1 (Fig. 5 c), were removed (Gregorio and
Fowler, 1995), as shown by a lack of immunofluorescent
detection. Actin filaments (Fig. 5, d and g), as well as the
major Z-line component 
 
 
 
-actinin, and titin filaments re-
mained intact in the extracted cells (unpublished data). Pu-
rified tropomyosin (Fig. 5 e) and recombinant Tmod1
(Fig. 5 f) were reconstituted on the existing actin filaments
(Fig. 5 g) and assembled in their typical sarcomeric distri-
butions. In fact, actin filaments alone, or those with tro-
pomyosin plus Tmod alone, were stable for 
 
 
 
60 min at
room temperature (unpublished data). Remarkably, the
addition of exogenous tropomyosin followed by a mixture
of recombinant Tmod1 with mAb17 (Fig. 5, l–o), or
Tmod1 with mAb8 (Fig. 5, p–s), resulted in a dramatic
loss of actin filaments (Fig. 5, m and q, respectively): a
phenotype that appeared identical to that observed in
intact cells. In contrast, reconstitution of tropomyosin
followed by the addition of a mixture of Tmod1 with
MOPC-21 (Fig. 5, h–k), the addition of mAb8 in the ab-
sence of Tmod1 (Fig. 5, t–v), or the addition of mAb8
with Tmod1 in the absence of reconstituted tropomyosin
(unpublished data) had no effect on the actin filaments.
These data indicate that once the actin–tropomyosin fila-
ments are capped by Tmod1, the interaction between
Tmod1 and tropomyosin must be intact to prevent depoly-
merization of the thin filaments (see Discussion).
To determine if stabilizing the actin filaments before
addition of mAb17 or mAb8 with Tmod1 would affect
Figure 4. Disrupting the interaction between Tmod and tropomyosin in live cardiac myocytes results in a perturbation of other sarcomeric 
components. Cardiac myocytes were microinjected with MOPC-21 Fabs (a, c, e, g, i, and k) or mAb17 Fabs (b, d, f, h, j, and l), incubated for 
1 h, fixed, and stained for tropomyosin (a and b, red),  -actinin (c, d, k, and l, red), myosin (e and f, red), I-band titin (g and h, red) or M-line 
titin (i and j, red; k and l, blue). Myocytes injected with mAb17 Fabs showed a loss of tropomyosin consistent with the loss of actin filaments (b). 
Myocytes injected with mAb17 or mAb17 Fabs displayed a perturbed staining pattern for  -actinin (d), myosin (f), and titin (h and j). Strikingly, 
myocytes injected with mAb17 Fabs displayed alternating M-line titin (l, blue) and  -actinin (l, red) staining in the absence of detectable actin 
(l, green). (inset) Enlarged view of l. (arrowheads) Closely spaced remnants of striated staining patterns. Bar, 10  m.T
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the loss of thin filaments, actin filaments were first stabi-
lized with jasplakinolide or phalloidin, before the recon-
stitution of tropomyosin and Tmod1 (Fig. 6, data shown
for phalloidin treatment). Strikingly, both tropomyosin
(Fig. 6, c, g, and k) and Tmod1 (Fig. 6, d, h, and l) re-
mained striated along the stabilized myofibrils after the
addition of the Tmod1–mAb17 mixture (Fig. 6 e) or
Tmod1–mAb8 mixture (Fig. 6 i). Thus, stabilization of
the actin filaments via phalloidin or jasplakinolide, before
disruption of the interaction of Tmod1 and tropomyosin,
was sufficient to prevent thin filament depolymerization.
These data from the reconstitution assay also suggest that
the thin filament disassembly phenotype observed is a di-
rect effect of disrupting the interaction of Tmod1 with
Figure 5. The disruption of the Tmod1–tropomyosin interaction in permeabilized and extracted cardiac myocytes results in the loss of 
actin filaments. (A) Cardiac myocytes permeabilized with saponin and extracted in 0.5 M KCl were stained for myosin (a), tropomyosin (b), 
or Tmod1 (c): all three sarcomeric components were extracted, whereas the actin filaments were unaffected (c and d, costained). Biotinylated 
tropomyosin (e) and recombinant Tmod1 (f) were reconstituted onto the ghost myofibrils (g). (B) Cardiac myocytes extracted and reconstituted 
with biotinylated tropomyosin followed by a mixture of Tmod1 with MOPC-21 (h–k) showed no disruption of the striated actin filaments (i), 
tropomyosin (j), and Tmod1 (k) upon addition of MOPC-21 (h and i; j and k, both costained). In contrast, the addition of mAb17 (l–o) or 
mAb8 (p–s) resulted in the loss of actin filaments (m and q), tropomyosin (n and r), and Tmod1 (o and s) (n and o; r and s, both costained). The 
addition of mAb8 (t) in the absence of recombinant Tmod1 had no effect on the actin filaments (u) or on tropomyosin (v). Bars, 10  m.T
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tropomyosin and is likely not influenced by other soluble,
regulatory, or sarcomeric components.
 
Discussion
 
In this work, we specifically blocked the interaction of
Tmod1 with one of its three known binding partners, tro-
pomyosin, in live chick cardiac myocytes. We disrupted this
interaction by microinjecting function-blocking antibodies
against the NH
 
2
 
-terminal region of Tmod1 and by microin-
jecting a recombinant NH
 
2
 
-terminal Tmod1 fragment con-
taining the tropomyosin binding site. These approaches re-
sulted in a striking phenotype: a loss of thin filaments and
cessation of contractile activity. To further investigate the
mechanism of this observed phenotype, we transfected myo-
cytes with GFP–
 
 
 
-tropomyosin, which assembled along the
lengths of the thin filaments, and then microinjected these
cells with mAb17. This live cell imaging strategy allowed us
to visualize the loss of thin filaments in real time, revealing
that the thin filaments depolymerized progressively from
their pointed ends. Results from a cell permeabilization assay
further revealed that the loss of thin filaments, upon pertur-
bation of the interaction of Tmod1 with tropomyosin, is
prevented by the prior stabilization of the actin filaments
with phalloidin or jasplakinolide. These observations reveal
exciting, novel functions for both tropomyosin and Tmod1.
For tropomyosin, our study provides direct support for its
proposed role as a thin filament stabilizing component in
vertebrate muscle. For Tmod1, we found that its two dis-
tinct structural and ligand-binding regions, the NH
 
2
 
-termi-
nal tropomyosin-binding domain and COOH-terminal ac-
tin capping domain, have unique roles at the pointed ends of
the thin filaments that can be distinguished in the context of
live myocytes. The interaction of Tmod1 with tropomyosin
at the pointed ends is critical for maintaining the integrity of
thin filaments, by preventing their depolymerization in live
cardiac myocytes (Fig. 7, I–III). The phenotype we observed
is strikingly different from the phenotype obtained from in-
hibiting the interaction of Tmod1 with actin, which re-
vealed that Tmod1’s capping activity is required to prevent
abnormal elongation of the thin filaments from their
pointed ends (Gregorio et al., 1995) (Fig. 7, IV–VI). To-
gether, we conclude that Tmod1 is a multifunctional pro-
tein in cardiac muscle, involved in maintaining the lengths
and stability of the thin filaments.
The exact mechanisms by which Tmod1–tropomyosin
interactions are critical for thin filament stability are puz-
zling based on many observations, mainly from in vitro
studies, that show that tropomyosin–coated actin filaments
are stable in the absence of Tmod1. For example, actin can
polymerize into long, stable filaments in the absence of
tropomyosin and Tmod1; and actin filaments saturated
with tropomyosin (but lacking Tmod1) depolymerize more
slowly from the pointed ends compared with naked actin fil-
aments. However, the ability of tropomyosin alone to pre-
vent actin depolymerization from the pointed ends in vitro
depends on the presence of a considerable excess of free tro-
pomyosin over the amount necessary to coat the actin fila-
ments (Broschat, 1990; Weber et al., 1994, 1999). This is
because binding of the terminal tropomyosin molecule at
Figure 6. Stabilization of thin filaments by phalloidin before addition of mAb17 or mAb8 prevents thin filament disruption. Cardiac 
myocytes were extracted and actin filaments were stabilized with AlexaFluor 488 phalloidin before the addition of tropomyosin and Tmod1. 
MOPC-21 was added to the myocytes (a–d) and had no apparent effect on actin filaments (b), tropomyosin (c), and Tmod1 (d) (a and b; c and d, 
both costained). Notably, the addition of mAb17 (e–h) or mAb8 (i–l) along with the purified Tmod1 had no effect on actin filaments (f and j), 
tropomyosin (g and k), and Tmod1 (h and l), which were stabilized by phalloidin (e,f; i,j; g,h; k,l, all costained). Bar, 10  m.T
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the pointed filament end is significantly weaker than that of
the other tropomyosin molecules, which self-associate with
neighboring tropomyosins along the thin filaments (Weg-
ner, 1979; Weber et al., 1999). In contrast, actin filaments
coated with tropomyosin and capped by Tmod1 at their
pointed ends are significantly more stable because Tmod1
enhances the ability of tropomyosin to reduce pointed end
depolymerization (Weber et al., 1994, 1999). Thus, Tmod1
may specifically promote stronger binding of the terminal
tropomyosin molecule to the thin filaments by virtue of its
ability to bind both actin and tropomyosin at the pointed
ends (Weber et al., 1999). Because there is essentially no ex-
cess free tropomyosin in chick cardiac myocytes (Gregorio
and Fowler, 1995) (i.e., all the available tropomyosin is as-
sembled onto the thin filaments and as a result, tropomyo-
sin concentrations are limiting), we speculate that Tmod1
interactions with tropomyosin may be essential to an-
chor the terminal tropomyosin molecules to the thin fila-
ment pointed ends in vivo. Thus, specific perturbation of
Tmod1–tropomyosin interactions in cardiac myocytes may
lead to weakened binding of the terminal tropomyosin mol-
ecule at thin filament pointed ends followed by coopera-
tive dissociation or “unzipping” of the entire tropomyosin
polymer from the thin filaments. This would be followed
by actin filament depolymerization, as we observed when
Tmod1–tropomyosin interactions were inhibited by mAb8
or mAb17. In this model, Tmod1 functions as a cap for
both the terminal tropomyosin and actin molecules, thereby
affecting pointed end stability, as well as tropomyosin and
actin dynamics.
Although this mechanism is an attractive model, it does
not fully account for a surprising result from our cardiac
myocyte thin filament reconstitution assays. Actin filaments
appear to be relatively stable in extracted cells (myocyte
ghosts) in the absence (or presence) of tropomyosin and
Tmod1; however, the addition of the anti–NH
 
2
 
-termi-
nal Tmod1 antibodies mAb8 or mAb17 appear to transform
Tmod1 (Fig. 7 III) such that it catalytically imparts instabil-
ity on what would otherwise be a relatively stable structure.
In other words, in these experiments, Tmod1 plus mAb8 or
mAb17 appears to behave like a “depolymerase” for tro-
pomyosin–actin filaments. Perhaps the binding of these an-
tibodies leads to a structural alteration in Tmod1 so that it
now actively disrupts actin–actin or actin–tropomyosin in-
teractions. Alternatively, such an altered Tmod1 may inter-
act differently with the giant protein nebulin (see Discus-
sion), causing a propagated destabilization down the length
of the filament, resulting in its disassembly. It is also plausi-
ble that a structural alteration occurs in the thin filament
once Tmod1 has associated with the pointed ends, causing
the filaments to become unstable if Tmod1–tropomyosin
interactions are perturbed. Our current experiments are ad-
dressing these intriguing issues.
An interesting, yet complex, question that arises is, how
does Tmod1 function with tropomyosin in stabilizing the
thin filaments given the fact that the pointed end compo-
nents are dynamic? GFP-Tmod1 and fluorescently labeled
actin monomers rapidly associate and dissociate from the
pointed ends in chick embryonic cardiac myocytes (Little-
field et al., 2001). Additionally, epitope-tagged tropomyosin
molecules, but not epitope-tagged troponin I molecules,
preferentially assemble onto the pointed ends of the thin fil-
aments in adult rat cardiac myocytes (Michele et al., 1999).
These studies and our results indicate that the slow-growing,
pointed ends of the thin filaments are not only dynamic
with respect to the rapid exchange of actin, tropomyosin,
and Tmod1 but are the critical site for both length regula-
tion and overall stability of the thin filaments. Exactly how
this occurs remains to be determined.
Although Tmod1 is a critical component for maintaining
and stabilizing thin filament lengths, there is no evidence
that Tmod1 is involved in specifying their lengths. How-
ever, several groups have identified nebulin, the Tmod1 and
tropomyosin-binding protein, as the prime candidate mole-
cule for functioning as a “ruler” to specify the precise lengths
of the thin filaments in skeletal muscle and, more recently,
in cardiac muscle (Fock and Hinssen, 2002; Kazmierski et
al., 2003; for review see McElhinny et al., 2003). In support
of this hypothesis, nebulin participates in the initial stages of
assembly of I-Z-I bodies, precursor structures that mature
Figure 7. Model of two identified 
functional domains of Tmod1. (I and IV) 
Stable thin filaments are comprised of 
actin (gray), tropomyosin (red), and 
Tmod1 (blue cap). (II) Disrupting the 
interaction of Tmod1 and tropomyosin 
(red) with mAb17 or mAb8 (black) 
appears to alter the functional properties 
of Tmod1 (blue square), which imparts 
instability at the pointed ends of the thin 
filaments. Note, the shape change is 
meant to indicate that Tmod1 acquires a 
new functionality, but the exact alteration 
is unknown. (III) The conferred instability 
results in a loss of thin filaments via 
depolymerization from the pointed ends. 
(V) In contrast, disrupting Tmod1’s actin 
capping activity with mAb9 results in an 
elongation of actin filaments at the 
pointed ends (VI). These results suggest at least two functional roles for Tmod1: stabilizing/preventing depolymerization of thin filaments 
through its interaction with tropomyosin, and inhibiting elongation/maintenance of actin filaments lengths through its actin capping activity.T
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into definitive Z-lines and I-bands (Ojima et al., 1999). Ad-
ditionally, in many studies nebulin is observed in a striated
pattern before the thin filaments attain their mature lengths,
which is consistent with the idea that nebulin dictates thin
filament architecture and restricts filament lengths (Shimada
et al., 1996; Moncman and Wang, 1996). Nebulin may also
act with tropomyosin as thin filament stabilizers during
myofibril assembly. Importantly, recent reports have sug-
gested a critical role for tropomyosin in myofibril assembly.
Specifically, genetic analysis of the Unc-60B (homologue of
cofilin/ADF) mutant in 
 
C. elegans
 
 (Ono and Ono, 2002) in-
dicated that actin filament assembly depends on a balance
between actin stabilization by tropomyosin and actin disas-
sembly mediated by cofilin/ADF. Tropomyosin has also
been implicated in playing an important role in zebrafish
myofibrillogenesis based on analyses of cardiac troponin T
(TNNT2) mutants; the loss of Tnnt2 expression in silent
heart (sih) mutants resulted in a significant reduction in tro-
pomyosin levels, causing sarcomere loss and myocyte disar-
ray (Sehnert et al., 2002). Furthermore, tropomyosin is im-
portant for myofibrillogenesis in the amphibian, Mexican
axolotl; that is, when mouse 
 
 
 
-tropomyosin was introduced
into mutant hearts (that showed a reduction of overall tro-
pomyosin expression), myofibrillogenesis and contractile ac-
tivity were restored (Zajdel et al., 1998). Given these data, it
is tempting to speculate the following model of thin fila-
ment assembly: when the actin–tropomyosin filaments at-
tain their mature lengths, nebulin’s NH
 
2
 
-terminal modules
target Tmod1 to the pointed ends of the thin filaments.
Once Tmod1 assembles, it functions to cap the actin and
tropomyosin polymers, thus stabilizing and maintaining the
lengths of the thin filaments at their pointed ends. We spec-
ulate that nebulin, tropomyosin, and Tmod1 play comple-
mentary, critical roles in controlling thin filament lengths
and stability. Furthermore, the regulated interactions among
these three thin filament components appear to be essential
for proper myofibril assembly, structure, and function.
Materials and methods
Purified proteins and anti-Tmod1 antibodies
Recombinant full-length chicken Tmod1 and Tmod1 fragments were gen-
erated in Escherichia coli as described in Babcock and Fowler (1994).
Monoclonal antibodies against recombinant chicken Tmod1 were gener-
ated by C. Grant (Custom Monoclonals, Sacramento, CA) and purified
from hybridoma supernatants using a protein G–Sepharose 4 Fast Flow
column (Amersham Pharmacia Biotech). The purified antibodies were dia-
lyzed to 1.0 mg/ml in injection buffer (1 mM Tris and 25 mM KCl, pH 7.4).
An irrelevant monoclonal antibody of the same isotype, MOPC-21 (Sigma-
Aldrich), was used as a control (Gregorio et al., 1995). Fabs of mAb17 and
MOPC-21 were generated by incubating the purified antibodies with pa-
pain-conjugated beads (Sigma-Aldrich), followed by isolation on a Mono
Q anion exchange column. Rabbit skeletal tropomyosin was purified as
described previously (Fowler, 1990).
Western blot analysis
0.5   g of full-length or fragments of Tmod1, and 20 ng of full-length
Tmod1 and equivalent molar amounts of fragments, were loaded for Coo-
massie blue staining and Western blot analysis, respectively. Blots were
probed as described previously (Gregorio et al., 1995).
The specificity of the anti-Tmod1 antibodies was determined from day 6
embryonic chick hearts. In brief, hearts were dissected, snap-frozen, and
ground in liquid nitrogen. The powder was solubilized in 2  SDS sample
buffer, run on a 10% gel, and transferred to nitrocellulose. Nitrocellulose
strips were incubated with either 0.5  g/ml of MOPC-21, mAb8, mAb17
or 1.0  g/ml mAb17 Fabs followed by HRP-conjugated anti–mouse IgG
(1:20,000). Blots were incubated in Super Signal chemiluminescent sub-
strate (Pierce Chemical Co.) and exposed to film (Biomax MR; Kodak).
Antibody competition and dissociation assays
5 pmol of full-length recombinant chicken Tmod1 were absorbed onto
nitrocellulose as spots using a dot blot apparatus and preincubated with
0–700 nM of mAb8, 9, or 17 for 3 h at RT in a final volume of 200  l (25
nM Tmod1). The molar ratio of mAb to Tmod1 varied from 1.3:1 at the
lowest antibody concentration used (33 nM) to 28:1 at the highest con-
centration used (700 nM). After several washes, dots were incubated
overnight at 4 C with 33 nM 
125I-Bolton Hunter–labeled rabbit skeletal
muscle tropomyosin in binding buffer (20 mM Hepes, 80 mM KCl, 2 mM
MgCl2,1 mM DTT, 0.2% Triton X-100, and 20 mg/ml BSA), and washed
to remove unbound tropomyosin. For the dissociation assay, 5 pmol
Tmod1 were adsorbed onto nitrocellulose dots and incubated with 33
nM 
125I-tropomyosin overnight at 4 C. After several washes, the Tmod1
dots were incubated with 330 nM mAb8 or MOPC-21 (molar ratio of
mAb/Tmod   13:1). The amount of bound 
125I-tropomyosin was quanti-
fied in a   counter.
Cell culture and microinjection procedures
Cardiac myocytes were isolated from day 6 embryonic chick hearts (Gre-
gorio and Fowler, 1995). Isolated cells were plated at 10
6 cells/dish in 35-
mm culture dishes containing CELLocate gridded coverslips (Eppendorf).
Cells cultured for 3–5 d were injected with a 0.3–1.0-mg/ml solution of
mAbs, Fabs, or purified Tmod1 fragments in injection buffer using a Trans-
jector (model 5246; Eppendorf) and micromanipulator (model 5171; Ep-
pendorf). Injected cells were incubated for 1–48 h before fixation.
Beating assays were performed by injecting beating cardiac myocytes
cultured for 4 d with mAb17 or MOPC-21. Cells were incubated for 1 h at
37 C and the percentage of injected cells that were beating was deter-
mined. Greater than 60 cells/coverslip were analyzed and the experiment
was performed in triplicate. Numbered grids on coverslips allowed for the
identification of microinjected cells.
Indirect immunofluorescence and deconvolution microscopy
Cardiac myocytes were fixed 1 h after injection in 5% formaldehyde/PBS
for 10 min, washed in PBS, and permeabilized in 0.2% Triton X-100/PBS
for 15 min. Coverslips were blocked in 2% BSA/1% donkey serum/PBS for
30 min. Microinjected cells were stained with an AlexaFluor 594–conju-
gated goat anti–mouse IgG (1:1,000) or a donkey Texas red–conjugated
anti–mouse IgG (Fab specific; 1:100) to detect the injected antibody. Actin
was visualized using an AlexaFluor 488–, 594– or 647 phalloidin, or a
monoclonal anti–cardiac actin antibody (Ac1-20.4.2; 1:10; American Re-
search Products) followed by a donkey Texas red–conjugated anti–mouse
IgG (Fc specific) antibody (1:100). For triple labeling, cells within num-
bered grids on the coverslip were injected with mAb17 Fabs or MOPC-21
Fabs and incubated for 1 h before fixation. Cells were incubated with
monoclonal sarcomeric anti– -actinin antibodies (1:1,500; EA-53; Sigma-
Aldrich), anti–myomesin B4 antibodies (1:50; provided by J-.C. Perriard
and E. Ehler, Institute for Cell Biology, Zurich, Switzerland; Grove et al.,
1984), or anti–myosin F59 antibodies (1:10; provided by F. Stockdale,
Stanford University, Stanford, CA) followed by FITC-conjugated anti–
mouse Fc-specific IgG (1:100). Anti–titin A168-A170 (1:100) or titin N2A
antibodies (10  g/ml) (Centner et al., 2000) were added, followed by Cy5-
conjugated donkey anti–rabbit IgG antibodies (1:600). Cells were incu-
bated in AlexaFluor 594 phalloidin. AlexaFluor-conjugated antibodies and
phalloidin were purchased from Molecular Probes. All other fluorescent
antibodies were purchased from Jackson ImmunoResearch Laboratories.
Cells were analyzed on a microscope (model IX70; Olympus). Micro-
graphs were recorded as digital images (with Z-series containing 0.15- m
sections) using a CCD camera (model Series 300; Photometrics) and de-
convolved using DeltaVision software (Applied Precision).
Transfection and live cell imaging
For live cell imaging, transfection was performed by incubating 1  g
pEGFP–rat– -tropomyosin (gift from J.-C. Perriard; Helfman et al., 1999)
with 7  l Cytofectene (Bio-Rad Laboratories) and 100  l Opti-MEM (Life
Technologies) for 15 min at RT and adding the mixture to cardiac myo-
cytes cultured for 24 h 3–4 d after transfection, cells were injected with
mAb17 or MOPC-21. Coverslips were placed into a Focht Live-cell Cham-
ber apparatus (Bioptechs) and Z-series of injected cells were imaged every
15 min. Staining with anti– -actinin antibodies allowed us to determine
the direction of depolymerization.T
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Cell permeabilization assay
The assay was performed as described previously (Gregorio and Fowler,
1995). Day 6 cardiac myocytes were permeabilized in relaxing buffer
(0.12 M KCl, 4 mM MgCl2, 20 mM Tris-HCl, pH 6.8, 4 mM EGTA, 4 mM
ATP, and 0.2 mg/ml saponin) for 10 min at 0 C, and then were extracted
in a high salt buffer (0.5 M KCl, 10 mM sodium pyrophosphate, 5 mM
MgCl2, 10 mM Tris-HCl, pH 6.5, 1 mM EGTA, and 0.2 mg/ml saponin) for
10 min at RT. Extracted cells were washed in incubation buffer (20 mM
KCl, 5 mM Tris-HCl, pH 6.8, 0.1 mM CaCl2, 0.1 mM ATP, and 0.2 mg/ml
saponin) for 15 s. To confirm the extraction, cells were fixed and stained
with anti–myosin F59, anti–tropomyosin CH1 (Lin et al., 1985), or anti-
Tmod1 monoclonal 95 antibodies (1:50; Almenar-Queralt et al., 1999)
followed by AlexaFluor 594–conjugated goat anti–mouse IgG (1:800) and
AlexaFluor 488 phalloidin. To reconstitute Tmod1 onto the myofibrils,
cells were first incubated with 50  g/ml biotinylated tropomyosin in 0.1
mM KCl, and 0.1 M Hepes, pH 7.5 for 10 min, rinsed, and then were in-
cubated with recombinant Tmod1 at 70  g/ml in 80 mM KCl, 2 mM
MgCl2, 0.1 mM DTT, and 20 mM Hepes, pH 7.3, in the presence of either
0.2 mg/ml of mAb17, mAb8, MOPC-21 or 0.05 mg/ml mAb17 Fabs for 25
min. After rinsing the cells in rigor buffer (60 mM KCl, 5 mM MgCl2, 1 mM
EGTA, 10 mM Tris-HCl, pH 6.8, and 0.2 mg/ml saponin) the cells were
fixed and stained for biotinylated tropomyosin using FITC-conjugated avi-
din (1:200; Zymed Laboratories) and Tmod1 using rabbit anti-Tmod1
1844 antibodies (1:100) followed by Cy5-conjugated donkey anti–rabbit
IgG antibodies (1:500). Actin was visualized using AlexaFluor 594 phalloi-
din. Stabilization of actin filaments was performed by adding either Alex-
aFluor 594 phalloidin for 20 min or 1  M jasplakinolide (Molecular
Probes) in DMSO for 7 min after the cells were extracted. Myocytes
treated with actin-stabilizing agents were reconstituted with tropomyosin
and Tmod1, fixed, and stained as described in the section Indirect immu-
nofluorescence and deconvolution microscopy.
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